Business Context and Reporting Period
Company: Redhill Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 13, 2022
Purpose: Refiling of Exhibit 99.1 (Asset Purchase Agreement dated August 11, 2010, with Giaconda Limited) to comply with Regulation S-K Item 601(b) requirements. The filing omits confidential information deemed not material but potentially harmful to competitive standing if disclosed.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural refiling of a historical contract and contains no financial statements or operational metrics for the reporting period.
Material Changes
No material changes to financial performance or operations are reported in this filing. The only change noted is the redaction of specific confidential information from a previously filed exhibit to align with current SEC regulations regarding material contracts.
Guidance, Outlook, and Risks
Management Commentary: None provided regarding future outlook or strategy.
Risks and Contingencies: The filing notes that the omitted confidential information would likely cause competitive harm if publicly disclosed. No other risks or contingencies are detailed in this specific document.
Key Facts for Investor Verification
- This filing contains no new financial data or operational updates.
- The document serves solely to update the public record of the 2010 Asset Purchase Agreement with Giaconda Limited.
- Investors should refer to the company's Form 20-F or recent quarterly reports for actual financial performance and guidance.